Dean Y. Li - Jan 9, 2024 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)

Role
Director
Signature
/s/ Jonathan Golightly, attorney-in-fact
Stock symbol
RXRX
Transactions as of
Jan 9, 2024
Transactions value $
-$396,214
Form type
4
Date filed
1/11/2024, 06:51 PM
Previous filing
Jan 4, 2024
Next filing
Jan 24, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RXRX Class A Common Stock Sale -$383K -28K -6.23% $13.65 422K Jan 9, 2024 By Dean Y. Li 2021 Family Trust F1, F2, F3
transaction RXRX Class A Common Stock Sale -$13.5K -962 -0.23% $14.03 421K Jan 9, 2024 By Dean Y. Li 2021 Family Trust F1, F3, F4
holding RXRX Class A Common Stock 1.33M Jan 9, 2024 Direct
holding RXRX Class A Common Stock 1.42M Jan 9, 2024 By Dean Y. Li Revocable Trust
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Sales are pursuant to a 10b5-1 trading plan established by the Trust on August 22, 2023.
F2 The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $13 to $13.99 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.
F3 The shares are held by the Dean Y. Li 2021 Family Trust, of which the Reporting Person's spouse serves as trustee.
F4 The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $14 to $14.08 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.